Art. -Nr.: HY-13425

Deguelin

(Synonyms: (-)-Deguelin; (-)-cis-Deguelin)

15 Cited Publications

Kundenbewertung

Based on 15 publication(s) in Google Scholar

Deguelin, a naturally occurring rotenoid, acts as a chemopreventive agent by blocking multiple pathways like PI3K-Akt, IKK-NF-κB, and MAPK-mTOR-survivin-mediated apoptosis. Deguelin binding to Hsp90 leads to a decreased expression of numerous oncogenic proteins, including MEK1/2, Akt, HIF1α, COX-2, and NF-κB.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.20%
CAS. Nr.: 522-17-8
Formel: C₂₃H₂₂O₆
Molecular Weight:394.42

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Deguelin Chemical Structure

CAS. Nr.: 522-17-8

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (15)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle Akt Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	6.05 μM Compound: 4	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 30784881]
Astrocyte	IC₅₀	>80 μM Compound: 1	Growth inhibition of Nf1 defective and Trp53 defective mouse primary astrocytes after 2 hrs by XTT assay Growth inhibition of Nf1 defective and Trp53 defective mouse primary astrocytes after 2 hrs by XTT assay	[PMID: 26467198]
HeLa	IC₅₀	0.22 μM Compound: 3	Inhibition of TNF-alpha-induced NF-kappaB activation in human HeLa cells by SEAP reporter gene assay Inhibition of TNF-alpha-induced NF-kappaB activation in human HeLa cells by SEAP reporter gene assay	[PMID: 18841906]
HEp-2	CC₅₀	26.5 μM Compound: 10	Cytotoxicity against human HEp-2 cells measured after 3 days by CellTiter 96 aqueous one solution assay (Rvb >100 microM) Cytotoxicity against human HEp-2 cells measured after 3 days by CellTiter 96 aqueous one solution assay (Rvb >100 microM)	[PMID: 38579352]
HEp-2	IC₅₀	0.4 μM Compound: 10	Antiviral activity against Human respiratory syncytial virus infected in human HEp-2 cells assessed as plaque reduction preincubated with cells 15 mins followed by viral infection for 2.5 hrs and measured after 3 days by crystal violet staining based micr Antiviral activity against Human respiratory syncytial virus infected in human HEp-2 cells assessed as plaque reduction preincubated with cells 15 mins followed by viral infection for 2.5 hrs and measured after 3 days by crystal violet staining based micr	[PMID: 38579352]
L5178Y	IC₅₀	0.2 μM Compound: 26	Cytotoxicity against mouse L5178Y cells by MTT assay Cytotoxicity against mouse L5178Y cells by MTT assay	[PMID: 28075580]
MCF7	IC₅₀	10.59 μM Compound: i	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 24 hrs by MTT assay	[PMID: 27376493]
MCF7	IC₅₀	8.17 μM Compound: 4	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 30784881]
NCI-H1299	IC₅₀	0.11 μM Compound: 1, (-)-Deguelin	Cytotoxicity against human H1299 cells after 3 days by MTS assay Cytotoxicity against human H1299 cells after 3 days by MTS assay	[PMID: 23186287]
NCI-H1299	IC₅₀	5.67 μM Compound: 4	Antiproliferative activity against human NCI-H1299 cells after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1299 cells after 72 hrs by MTT assay	[PMID: 30784881]
RAW264.7	IC₅₀	1.75 μM Compound: 3	Inhibition of LPS-induced NF-kappaB activation in mouse RAW264.7 cells by SEAP reporter gene assay Inhibition of LPS-induced NF-kappaB activation in mouse RAW264.7 cells by SEAP reporter gene assay	[PMID: 18841906]
U-937	IC₅₀	16 μM Compound: 1, deguelin	Antiproliferative activity against human U937 cells after 48 hrs by WST-8 assay Antiproliferative activity against human U937 cells after 48 hrs by WST-8 assay	[PMID: 17158054]
U-937	IC₅₀	42 μM Compound: 1, deguelin	Antiproliferative activity against human U937 cells after 24 hrs by WST-8 assay Antiproliferative activity against human U937 cells after 24 hrs by WST-8 assay	[PMID: 17158054]
U-937	IC₅₀	5.8 μM Compound: 1, deguelin	Antiproliferative activity against human U937 cells after 72 hrs by WST-8 assay Antiproliferative activity against human U937 cells after 72 hrs by WST-8 assay	[PMID: 17158054]

In Vitro

Deguelin (0-500 nM) in a dose and time dependent manner inhibits the growth of MDA-MB-231, MDA-MB-468, BT-549 and BT-20 cells. Deguelin at all concentrations fails to reduce cell numbers in the presence of 1 ng EGF but in the presence of EGF 20 ng reinstated deguelin mediated growth inhibition. Deguelin treated cells show reduced expression of Survivin as determined by western blot and immunofluorescence examinations. Deguelin inhibits p-ERK and its downstream target p-STAT-3 and c-Myc expression in a dose dependent manner^[1].
Deguelin down-regulates Akt signaling probably by disrupting its association with Hsp 90 in cultured HNSCC cells. Deguelin deguelin disrupts the association between Hsp 90 with survivin and Cdk4. Deguelin deguelin treatment increases cellular ceramide level through de novo synthase pathway to mediate HNSCC cell death and apoptosis^[2].
Deguelin inhibits the proliferation of MPC-11 cells in a concentration- and time-dependent manner and causes the apoptotic death of MPC-11 cells. Following exposure to deguelin, the phosphorylation of Akt is decreased. Deguelin-induced apoptosis is characterized by the upregulation of Bax, downregulation of Bcl-2 and activation of caspase-3^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Deguelin (2 or 4 mg/kg, i.p.) reduces the in vivo tumor growth of MDA-MB-231 cells transplanted subcutaneously in athymic mice^[1].
Deguelin (4 mg/kg, p.o.) treatment shows a great inhibition in tumor growth, which is demonstrated by reduced tumor size and improved mice survival and, indicating a significant anti-tumor ability by deguelin in vivo^[2].
In the colon cancer xenograft model, the volume of the tumor treated with deguelin is significantly lower than that of the control, and the apoptotic index for deguelin-treated mice is much higher^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 522-17-8
Appearance Solid
Molecular Weight 394.42
Formel C₂₃H₂₂O₆
Color Light yellow to yellow
SMILES

O=C1[C@]2([H])[C@](COC3=CC(OC)=C(OC)C=C32)([H])OC4=C5C=CC(C)(C)OC5=CC=C14
Synonyms

(-)-Deguelin; (-)-cis-Deguelin
Structure Classification
- Flavonoids
- Isoflavanones
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (15)

All Cell Proliferation/Viability AssayWBApoptosis AnalysisCell Imaging/StainingIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

Acta Pharm Sin B

Chrysin serves as a novel inhibitor of DGK α/FAK interaction to suppress the malignancy of esophageal squamous cell carcinoma (ESCC). [Abstract]

2021 Jan;11(1):143-155. PMID: 33532186
Food Chem

Effects of sun drying combined with baking processes on the flavor quality of Chongqing Tuocha raw tea. [Abstract]

2025 Dec 30:497:146992. PMID: 41285060
Acta Pharmacol Sin

Deguelin inhibits growth and prolactin synthesis in prolactinomas by targeting the PI3K/AKT/CREB3L1 pathway and ornithine decarboxylase. [Abstract]

2025 Nov 3. PMID: 41184622

Deguelin purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2025 Nov 3. [Abstract]

Deguelin concentration response curves for both cell lines, as determined by the CCK-8 assay.

Deguelin purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2025 Nov 3. [Abstract]

Western blot analysis showing the levels of BCL-2, BAX in GH3 cells treated with Deguelin (0.1, 0.3, 1, 3 μM).

Deguelin purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2025 Nov 3. [Abstract]

Apoptosis analysis based on cell flow cytometry of two cell lines treated with different doses of Deguelin (1, 0.3, 1 μM) for 48 h.

Deguelin purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2025 Nov 3. [Abstract]

Colony formation assay of GH3 cells treated with different doses of Deguelin (0.1, 0.3, 1, 3 μM).

Deguelin purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2025 Nov 3. [Abstract]

Deguelin (4 mg/kg, i.p.) significantly inhibited GH3 tumor growth in vivo.
Food Chem

Flavonoid-mediated metabolic underpinning quality variation in red bud-sport pear mutants. [Abstract]

2025 May 31:489:144992. PMID: 40466530
Int J Mol Med

Deguelin exerts anticancer activity of human gastric cancer MGC-803 and MKN-45 cells in vitro. [Abstract]

2018 Jun;41(6):3157-3166. PMID: 29512685

Deguelin purchased from MedChemExpress. Usage Cited in: Int J Mol Med. 2018 Jun;41(6):3157-3166. [Abstract]

MGC-803 and MKN-45 cells are treated with increasing doses of Deguelin (0, 1 and 10 μM) for 6 h and harvested for western blot (WB) analysis to assess the p-Akt signaling.
PLoS Biol

A high-throughput behavioral screening platform for measuring chemotaxis by C. elegans. [Abstract]

2024 Jun 27;22(6):e3002672. PMID: 38935621
Cancer Biol Ther

Deguelin inhibits perineural invasion in esophageal squamous cell carcinoma via targeting BDNF/TrkB axis. [Abstract]

2026 Dec 31;27(1):2644788. PMID: 41851958
Neuropharmacology

Deguelin inhibits the glioblastoma progression through suppressing CCL2/NFκB signaling pathway. [Abstract]

2024 Aug 9:110109. PMID: 39128581
J Med Virol

E3 ubiquitin ligase FBXO22 inhibits SARS-CoV-2 replication via promoting proteasome-dependent degradation of NSP5. [Abstract]

2024 Sep;96(9):e29891. PMID: 39223933
Toxicol Appl Pharmacol

Deguelin inhibits IL-1β-induced chondrocyte inflammation in vitro and ameliorates murine osteoarthritis in vivo. [Abstract]

2025 Sep:502:117453. PMID: 40582373
Arch Med Res

microRNA-103 Contributes to Progression of Polycystic Ovary Syndrome Through Modulating the IRS1/PI3K/AKT Signal Axis. [Abstract]

2021 Jul;52(5):494-504. PMID: 33583602
Int J Biochem Cell Biol

Estradiol facilitates urate excretion by reducing GLUT9 expression via ERβ/TMEM106B/PI3K/AKT1 pathway in renal tubular epithelial cells. [Abstract]

2026 Jun-Jul:195-196:106940. PMID: 41825791
J Cancer

Tephrosin induces apoptosis of human pancreatic cancer cells through the generation of reactive oxygen species. [Abstract]

2021 Jan 1;12(1):270-280. PMID: 33391424
Res Sq

2025 Aug 20.
bioRxiv

An efficient behavioral screening platform classifies natural products and other chemical cues according to their chemosensory valence in C. elegans. [Abstract]

2024 Apr 3:2023.06.02.542933. PMID: 37333363

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (253.54 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5354 mL

12.6768 mL

25.3537 mL

5 mM

0.5071 mL

2.5354 mL

5.0707 mL

10 mM

0.2535 mL

1.2677 mL

2.5354 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.34 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (6.34 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.34 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Kinase Assay^[2]

Caspase 3 activity is determined using Caspase-Glo-3 assays. This assay provides luminogenic substrate in a buffer system optimized for each specific caspase activity. The caspase cleavage of the substrate is followed by generation of a luminescent signal. The signal generated is proportional to the amount of caspase activity present in the sample. Protein (10 µg) from the cell samples is diluted in water to a final volume of 50 µL and added to a white 96-well microtitre plate, followed by 50 µL of Caspase-Glo-3 reagent. The plate is sealed and gently mixed at 300-500 rpm for 30 s and incubated at room temperature for 30 min. Luminescence is measured in a microplate reader (TECAN Infinite 200).

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay^[1]

Breast cancer cells are incubated with increasing concentration of Deguelin ranging from 31 nM to 500 nM for 24, 48 and 72 h. At the termination the cells are trypsinized and cell proliferation is evaluated by counting cells using Z-series Coulter counter. Data are presented as Mean±SE percent of control.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]

Six to seven weeks old female athymic mice (nu/nu) are housed in a barrier free environment under 24±2°C temperature, 50±10% relative humidity, and 12-hour light/12-hour dark cycle. Mice are provided with sterile mouse chow and water ad libitum. MDA-MB-231 cells (3.0 million cells/animal) are suspended in sterile PBS and then injected subcutaneously into the dorsal flank region using 23 g hypodermic needle. Animals are observed daily for the growth of palpable tumor at the site of injection. Once the tumor (approximately 50 mm³) appears, the mice are randomized in to three groups, animals receiving either 1) vehicle as a control 2) Deguelin treatment at 2 mg/kg bodyweight dose or 3) Deguelin at 4 mg/kg body weight. Each group consists of 10 animals. Vehicle or Deguelin is administered through i.p. injection daily for 21 days. Animals are monitored daily for the signs of drug/vehicle associated toxicity and weighed once weekly. Growth of tumor at the site of cell injection is monitored every alternate day and of tumor size is measured using calipers. Tumor volume is calculated by using the well-established formula: tumor volume (mm³)=π/6 length×width×depth. Data represent the mean tumor volume+SE (mm³) in each group. The animals are sacrificed at the indicated time unless they appear to be moribund or tumors show sign of necrosis. At termination, the tumor is excised, freed from connective tissue and other organs, a small piece is fixed in 10% buffered formalin and remaining tumor is snap frozen for future biochemical analysis. Liver, lung, kidney and spleen are excised and weighed.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Mehta R, et al. Deguelin action involves c-Met and EGFR signaling pathways in triple negative breast cancer cells. PLoS One. 2013 Jun 10;8(6):e65113. [Content Brief]

[2]. Yang YL, et al. Deguelin induces both apoptosis and autophagy in cultured head and neck squamous cell carcinoma cells. PLoS One. 2013;8(1):e54736. [Content Brief]

[3]. Li Z, et al. Deguelin, a natural rotenoid, inhibits mouse myeloma cell growth in vitro via induction of apoptosis. Oncol Lett. 2012 Oct;4(4):677-681. [Content Brief]

[4]. Kang HW, et al. Deguelin, an Akt inhibitor, down-regulates NF-κB signaling and induces apoptosis in colon cancer cells and inhibits tumor growth in mice. Dig Dis Sci. 2012 Nov;57(11):2873-82. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.5354 mL	12.6768 mL	25.3537 mL	63.3842 mL
	5 mM	0.5071 mL	2.5354 mL	5.0707 mL	12.6768 mL
	10 mM	0.2535 mL	1.2677 mL	2.5354 mL	6.3384 mL
	15 mM	0.1690 mL	0.8451 mL	1.6902 mL	4.2256 mL
	20 mM	0.1268 mL	0.6338 mL	1.2677 mL	3.1692 mL
	25 mM	0.1014 mL	0.5071 mL	1.0141 mL	2.5354 mL
	30 mM	0.0845 mL	0.4226 mL	0.8451 mL	2.1128 mL
	40 mM	0.0634 mL	0.3169 mL	0.6338 mL	1.5846 mL
	50 mM	0.0507 mL	0.2535 mL	0.5071 mL	1.2677 mL
	60 mM	0.0423 mL	0.2113 mL	0.4226 mL	1.0564 mL
	80 mM	0.0317 mL	0.1585 mL	0.3169 mL	0.7923 mL
	100 mM	0.0254 mL	0.1268 mL	0.2535 mL	0.6338 mL

Keywords

Deguelin

15 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Deguelin

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Lipid Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Flavonoids Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Glucose Metabolism Compound Library

Food-Sourced Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Mitochondrial Toxicity Compound Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Extracellular Vesicles (EVs) Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

Posttranslational Modification Library

Natural Product Diversity Scaffold Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Deguelin

Alle Akt Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (15)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Deguelin Related Classifications

HY-13425 Related Classifications